<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156096">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01067677</url>
  </required_header>
  <id_info>
    <org_study_id>1-Cladis</org_study_id>
    <nct_id>NCT01067677</nct_id>
  </id_info>
  <brief_title>Rescue Emetic Therapy for Children Having Elective Surgery</brief_title>
  <acronym>RETCHES</acronym>
  <official_title>Rescue Emetic Therapy for Children Having Elective Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare ondansetron, metoclopramide, diphenhydramine, and placebo in order to determine
      which anti-emetic is most efficacious as a &quot;rescue therapy&quot; for pediatric patients ages 3-18
      who have post-operative vomiting after a standardized prophylactic regimen of ondansetron
      and dexamethasone. We hypothesize that anti-emetics with a different mechanism of action
      than the prophylactic regimen will be the most effective &quot;rescue therapy&quot; in children having
      surgery in an ambulatory surgery center.

        1. Problem: Despite commonly-used anti-emetics for prophylaxis, some children still go on
           to develop post-operative vomiting (POV).

           Goal: To determine which anti-emetic--ondansetron, metoclopramide, diphenhydramine, or
           placebo--is most efficacious for pediatric patients in this situation.

        2. Hypothesis: Anti-emetic medications that have a different mechanism of action than the
           prophylactic regimen will be the most efficacious &quot;rescue therapy.&quot;

        3. Hypothesis: Metoclopramide at the dose of 0.5 mg/kg (max dose 20 mg) will be more
           effective than ondansetron, diphenhydramine, or placebo as &quot;rescue therapy.&quot;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary-Incidence of POV after rescue antiemetic in PACU, car ride home, day of surgery, and POD #1 and 2</measure>
    <time_frame>48 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary - a. Discharge times</measure>
    <time_frame>48 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (headaches, sedation, dystonic reaction, dry mouth)</measure>
    <time_frame>48 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>POV risk factors. age, personal or family history of PONV, history of motion sickness, personal or family history of smoking</measure>
    <time_frame>48 hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Post Operative Nausea and Vomiting</condition>
  <condition>Rescue Emetic Therapy</condition>
  <arm_group>
    <arm_group_label>Metoclopramide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rescue emetic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ondansetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rescue emetic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diphenhydramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rescue emetic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metaclopramide</intervention_name>
    <description>0.5 mg/kg for rescue after PONV</description>
    <arm_group_label>Metoclopramide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>0.1 mg/kg (max 4 mg0</description>
    <arm_group_label>Ondansetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diphenhydramine</intervention_name>
    <description>0.25 mg/kg (max 25 mg)</description>
    <arm_group_label>Diphenhydramine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>equal volume (5 ml)as experimental rescue medications</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pediatric patients 3-17 years old

          2. Patients scheduled for tonsillectomy and/or adenoidectomy (with and without
             myringotomy) , or dental restoration,

          3. Patients receiving a general anesthetic (inhaled agent without nitrous oxide) with
             POV prophylaxis with two agents (ondansetron and dexamethasone)

          4. Post operative vomiting in PACU or second stage recovery requiring antiemetic rescue.

        Exclusion Criteria:

          1. Vomiting in the past 24 hours or antiemetics in previous 24 hours

          2. Allergy or sensitivity to ondansetron, dexamethasone, metoclopramide, or
             diphenhydramine

          3. Patients with diabetes

          4. Patients with seizures

          5. Patients receiving a benzodiazepine premedication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franklyn P Cladis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franklyn P Cladis, MD</last_name>
    <phone>412-692-5260</phone>
    <email>cladfp@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franklyn P Cladis, MD</last_name>
      <phone>412-692-5260</phone>
      <email>cladfp@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Franklyn P Cladis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathy Fertal, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Slava Martyn</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Woelfel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neal Campbell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <lastchanged_date>June 21, 2011</lastchanged_date>
  <firstreceived_date>February 10, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Franklyn Cladis MD</name_title>
    <organization>University of Pittsburgh, Department of Anesthesiology</organization>
  </responsible_party>
  <keyword>PONV</keyword>
  <keyword>Post operative nausea and vomiting</keyword>
  <keyword>rescue emetic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Emetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
